BioCentury
ARTICLE | Clinical News

Serlopitant: Ph II ATOMIK (MTI-103) started

January 12, 2017 10:16 PM UTC

Menlo began the double-blind, placebo-controlled, U.S. Phase II ATOMIK (MTI-103) trial to evaluate 2 dose levels of oral serlopitant in about 450 patients. Menlo has exclusive, worldwide rights to ser...